GOLIMUMAB: CLINICAL UPDATE ON ITS USE FOR ULCERATIVE COLITIS
2015-01-01 Gilardi, D; Fiorino, G; Allocca, M; Bravata, I; Danese, S
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
2014-01-01 Panaccione, R; Ghosh, S; Middleton, S; Marquez, Jr; Scott, Bb; Flint, L; Van Hoogstraten, Hjf; Chen, Ac; Zheng, Hz; Danese, S; Rutgeerts, P
Mesenteric Vascular Thromboembolism in Inflammatory Bowel Disease: A Single Center Experience
2011-01-01 Jackson, Cs; Fryer, J; Danese, S; Vanagunas, A; Polensky, S; Buchman, Al
Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
2019-01-01 Roda, G; Porru, E; Katsanos, K; Skamnelos, A; Kyriakidi, K; Fiorino, G; Christodoulou, D; Danese, S; Roda, A
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy
2017-01-01 Furfaro, F; Gilardi, D; Allocca, M; Cicerone, C; Correale, C; Fiorino, G; Danese, S
Granulocyte colony-stimulating factor: A novel mediator of T cell tolerance
2005-01-01 Rutella, S; Zavala, F; Danese, S; Kared, H; Leone, G
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
2016-01-01 Bonovas, S; Fiorino, G; Allocca, M; Lytras, T; Nikolopoulos, Gk; Peyrin-Biroulet, L; Danese, S
Is It Crohn's Disease?
2020-01-01 Parigi, Tommaso Lorenzo; Bonifacio, Cristiana; Danese, Silvio
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
2021-01-01 Sandborn, William J; Feagan, Brian G; Danese, Silvio; O'Brien, Christopher D; Ott, Elyssa; Marano, Colleen; Baker, Thomas; Zhou, Yiying; Volger, Sheri; Tikhonov, Ilia; Gasink, Christopher; Sands, Bruce E; Ghosh, Subrata
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
2019-01-01 Pouillon, L; Baumann, C; Rousseau, H; Choukour, M; Andrianjafy, C; Danese, S; Peyrin-Biroulet, L
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
2013-01-01 Allocca, M; Jovani, M; Fiorino, G; Schreiber, S; Danese, S
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block
2020-01-01 Fiorino, G; Allocca, M; Correale, C; Roda, G; Furfaro, F; Loy, L; Zilli, A; Peyrin-Biroulet, L; Danese, S
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
2019-01-01 Reinisch, W; Bressler, B; Curtis, R; Parikh, A; Yang, H; Rosario, M; Roseth, A; Danese, S; Feagan, B; Sands, Be; Ginsburg, P; Dassopoulos, T; Lewis, J; Xu, J; Wyant, T
Platelet activation and the CD40/CD40 ligand pathway: Mechanisms and implications for human disease
2005-01-01 Danese, S; Fiocchi, C
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey
2018-01-01 Olivera, P; Sandborn, Wj; Panes, J; Baumann, C; D'Haens, G; Vermeire, S; Danese, S; Peyrin-Biroulet, L
Evolving Treatment Algorithms in Crohn's Disease
2018-01-01 Wisniewski, A; Danese, S; Peyrin-Biroulet, L
Vedolizumab for the treatment of Crohn's disease
2018-01-01 Argollo, M; Fiorino, G; Peyrin-Biroulet, L; Danese, S
Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities
2016-01-01 Danese, S; Vermeire, S
JAK selectivity: more precision less troubles
2020-01-01 Roda, Giulia; Dal Buono, Arianna; Argollo, Marjorie; Danese, Silvio
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis
2017-01-01 Allen, Pb; Olivera, P; Emery, P; Moulin, D; Jouzeau, Jy; Netter, P; Danese, S; Feagan, B; Sandborn, Wj; Peyrin-Biroulet, L
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| GOLIMUMAB: CLINICAL UPDATE ON ITS USE FOR ULCERATIVE COLITIS | 1-gen-2015 | Gilardi, D; Fiorino, G; Allocca, M; Bravata, I; Danese, S | |
| Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis | 1-gen-2014 | Panaccione, R; Ghosh, S; Middleton, S; Marquez, Jr; Scott, Bb; Flint, L; Van Hoogstraten, Hjf; Chen, Ac; Zheng, Hz; Danese, S; Rutgeerts, P | |
| Mesenteric Vascular Thromboembolism in Inflammatory Bowel Disease: A Single Center Experience | 1-gen-2011 | Jackson, Cs; Fryer, J; Danese, S; Vanagunas, A; Polensky, S; Buchman, Al | |
| Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs | 1-gen-2019 | Roda, G; Porru, E; Katsanos, K; Skamnelos, A; Kyriakidi, K; Fiorino, G; Christodoulou, D; Danese, S; Roda, A | |
| IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy | 1-gen-2017 | Furfaro, F; Gilardi, D; Allocca, M; Cicerone, C; Correale, C; Fiorino, G; Danese, S | |
| Granulocyte colony-stimulating factor: A novel mediator of T cell tolerance | 1-gen-2005 | Rutella, S; Zavala, F; Danese, S; Kared, H; Leone, G | |
| Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis | 1-gen-2016 | Bonovas, S; Fiorino, G; Allocca, M; Lytras, T; Nikolopoulos, Gk; Peyrin-Biroulet, L; Danese, S | |
| Is It Crohn's Disease? | 1-gen-2020 | Parigi, Tommaso Lorenzo; Bonifacio, Cristiana; Danese, Silvio | |
| Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies | 1-gen-2021 | Sandborn, William J; Feagan, Brian G; Danese, Silvio; O'Brien, Christopher D; Ott, Elyssa; Marano, Colleen; Baker, Thomas; Zhou, Yiying; Volger, Sheri; Tikhonov, Ilia; Gasink, Christopher; Sands, Bruce E; Ghosh, Subrata | |
| Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience | 1-gen-2019 | Pouillon, L; Baumann, C; Rousseau, H; Choukour, M; Andrianjafy, C; Danese, S; Peyrin-Biroulet, L | |
| Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target | 1-gen-2013 | Allocca, M; Jovani, M; Fiorino, G; Schreiber, S; Danese, S | |
| Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block | 1-gen-2020 | Fiorino, G; Allocca, M; Correale, C; Roda, G; Furfaro, F; Loy, L; Zilli, A; Peyrin-Biroulet, L; Danese, S | |
| Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1 | 1-gen-2019 | Reinisch, W; Bressler, B; Curtis, R; Parikh, A; Yang, H; Rosario, M; Roseth, A; Danese, S; Feagan, B; Sands, Be; Ginsburg, P; Dassopoulos, T; Lewis, J; Xu, J; Wyant, T | |
| Platelet activation and the CD40/CD40 ligand pathway: Mechanisms and implications for human disease | 1-gen-2005 | Danese, S; Fiocchi, C | |
| Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey | 1-gen-2018 | Olivera, P; Sandborn, Wj; Panes, J; Baumann, C; D'Haens, G; Vermeire, S; Danese, S; Peyrin-Biroulet, L | |
| Evolving Treatment Algorithms in Crohn's Disease | 1-gen-2018 | Wisniewski, A; Danese, S; Peyrin-Biroulet, L | |
| Vedolizumab for the treatment of Crohn's disease | 1-gen-2018 | Argollo, M; Fiorino, G; Peyrin-Biroulet, L; Danese, S | |
| Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities | 1-gen-2016 | Danese, S; Vermeire, S | |
| JAK selectivity: more precision less troubles | 1-gen-2020 | Roda, Giulia; Dal Buono, Arianna; Argollo, Marjorie; Danese, Silvio | |
| Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis | 1-gen-2017 | Allen, Pb; Olivera, P; Emery, P; Moulin, D; Jouzeau, Jy; Netter, P; Danese, S; Feagan, B; Sandborn, Wj; Peyrin-Biroulet, L |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista40134
Data di pubblicazione
- In corso di stampa9
- 2020 - 202712186
- 2010 - 201915980
- 2000 - 20097460
- 1990 - 19993486
- 1980 - 1989935
- 1970 - 197977
- 1959 - 19591
Editore
- Elsevier Inc.823
- Elsevier B.V.809
- Springer Science and Business Med...552
- John Wiley and Sons Inc549
- Oxford University Press506
- Lippincott Williams and Wilkins435
- Springer374
- Elsevier Ltd350
- MDPI348
- Springer Nature296
Rivista
- EUROPEAN UROLOGY535
- BLOOD372
- PLOS ONE313
- JOURNAL OF NEUROLOGY291
- EUROPEAN JOURNAL OF HEART FAILURE281
- NEUROLOGY270
- DIGESTIVE AND LIVER DISEASE245
- EUROPEAN HEART JOURNAL225
- MULTIPLE SCLEROSIS219
- SCIENTIFIC REPORTS215
Keyword
- Humans3553
- Male2080
- Female1864
- Middle Aged1472
- Aged1290
- Adult1100
- COVID-19636
- Retrospective Studies628
- Treatment Outcome603
- Prognosis483
Lingua
- eng29490
- ita1971
- fre65
- und55
- spa34
- ger26
- por12
- enm6
- rus6
- grc3
Accesso al fulltext
- no fulltext32003
- reserved4297
- open3722
- partially open104
- embargoed7
- mixed1